COMPANY RESEARCHNanobiotix SA
Nanobiotix is a French clinical-stage biotechnology company developing physics-based therapeutic approaches, including injectable nanoparticles intended to enhance local treatment effects when activated by radiotherapy. Its work targets cancers and aims to expand the potential of established radiation treatment through investigational nanomedicine technologies. The company has clinical research and development activities with external partners, and its programs remain subject to regulatory evaluation. Nanobiotix ordinary shares trade on Euronext Paris under NANO, and its American depositary shares trade on Nasdaq under NBTX.
Company at a glance
Corporate information
- Company entity
- Nanobiotix SA
- Headquarters / principal office
- France
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.nanobiotix.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Euronext Paris: NANO Nasdaq: NBTX
therapeutic nanomedicine · radiation activated nanoparticles
oncology
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Nanobiotix is a French clinical-stage biotechnology company developing physics-based therapeutic approaches, including injectable nanoparticles intended to enhance local treatment effects when activated by radiotherapy. Its work targets cancers and aims to expand the potential of established radiation treatment through investigational nanomedicine technologies. The company has clinical research and development activities with external partners, and its programs remain subject to regulatory evaluation. Nanobiotix ordinary shares trade on Euronext Paris under NANO, and its American depositary shares trade on Nasdaq under NBTX.
Business, technology & evidence
- SecuritiesEuronext Paris: NANO / Nasdaq: NBTX
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Nanobiotix SA ↗Nanobiotix SA ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.